Haemonetics/$HAE
1D1W1MYTD1Y5YMAX
About Haemonetics
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.
- Ticker
- $HAE
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 3,009
- Headquarters
- Boston, United States
- Website
- www.haemonetics.com
Haemonetics Metrics
BasicAdvanced
$4.6B
49.52
$2.06
0.52
-
Price and volume
Market cap
$4.6B
Beta
0.52
52-week high
$109.57
52-week low
$47.32
Average daily volume
802K
Financial strength
Current ratio
3.08
Quick ratio
1.674
Long term debt to equity
139.673
Total debt to equity
140.265
Interest coverage (TTM)
9.30%
Profitability
EBITDA (TTM)
358.786
Gross margin (TTM)
59.33%
Net profit margin (TTM)
7.12%
Operating margin (TTM)
18.85%
Effective tax rate (TTM)
26.18%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
6.60%
Return on equity (TTM)
11.20%
Valuation
Price to earnings (TTM)
49.516
Price to revenue (TTM)
3.506
Price to book
5.54
Price to tangible book (TTM)
-18.23
Price to free cash flow (TTM)
16.276
Free cash flow yield (TTM)
6.14%
Free cash flow per share (TTM)
6.264
Growth
Revenue change (TTM)
0.44%
Earnings per share change (TTM)
-37.17%
3-year revenue growth (CAGR)
3.53%
10-year revenue growth (CAGR)
4.09%
3-year earnings per share growth (CAGR)
-8.20%
10-year earnings per share growth (CAGR)
4.77%
What the Analysts think about Haemonetics
Analyst ratings (Buy, Hold, Sell) for Haemonetics stock.
Haemonetics Financial Performance
Revenues and expenses
Haemonetics Earnings Performance
Company profitability
Haemonetics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.